About This Site

Our Mission

We aim to make scientific and clinical information about retatrutide accessible to researchers, healthcare professionals, and the public. In a landscape where pharmaceutical information is often fragmented across multiple sources, our mission is to provide a single, authoritative, regularly updated resource that presents the evidence clearly and without bias.

All content is sourced from peer-reviewed publications, clinical trial registries, and official regulatory documents. We do not accept pharmaceutical industry funding and maintain full editorial independence.

What is Retatrutide?

Retatrutide is an investigational triple hormone receptor agonist that targets three key metabolic pathways simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This unique triple-agonist mechanism distinguishes it from other incretin-based therapies currently available or in development.

Editorial Standards

Every article on this site follows strict editorial standards designed to ensure accuracy, transparency, and clinical relevance:

• All articles cite primary sources and peer-reviewed research
• Content is categorized by evidence level (high, moderate, low, emerging)
• Articles are regularly updated as new data becomes available
• We maintain editorial independence with no pharmaceutical industry funding
• Each piece is reviewed for factual accuracy before publication
• Clearly distinguished between established evidence and preliminary findings

Editorial Team

Content on this site is developed and maintained by an independent editorial team with backgrounds in biomedical sciences, clinical pharmacology, and medical communications.

All articles undergo a multi-step review process: initial research and drafting, factual accuracy verification against primary sources, and final editorial review for clarity and balance.

While we do not publish individual author names to protect editorial independence from external pressure, our commitment to accuracy is demonstrated through our transparent citation practices and open correction policy.

Content Review Schedule

• Knowledge base articles are reviewed on a quarterly basis or whenever significant new data is published
• Clinical trial pages are updated within 48 hours of new results being publicly released
• Blog posts reflect the most current information available at publication date
• All pages display "Last Updated" dates for transparency

Content Methodology

Our editorial process follows a systematic approach to ensure rigor and consistency:

1. Source identification: We monitor PubMed, ClinicalTrials.gov, FDA databases, major medical conferences (ADA, EASD, ObesityWeek), and manufacturer press releases for relevant data.
2. Evidence assessment: Each source is evaluated for study design, sample size, statistical rigor, and potential bias. We assign evidence levels accordingly.
3. Content creation: Articles are written to accurately represent the published evidence without overstatement or speculation.
4. Review and update: Published articles are reviewed on a regular cycle and updated when new evidence emerges. All updates are dated and noted.

How to Cite This Resource

If you wish to reference content from this knowledge base in academic or professional work, please use the following format:

Retatrutide Knowledge Base. "[Article Title]." retatrutide.med, [Publication Date]. [URL]. Accessed [Access Date].

For example:

Retatrutide Knowledge Base. "Mechanism of Action." retatrutide.med, March 1, 2026. https://retatrutide.med/knowledge-base/mechanism-of-action. Accessed March 16, 2026.

Important Notice

This website does not sell any products or medications. It exists solely as an educational and informational resource. Retatrutide is an investigational medication that has not yet received regulatory approval in most countries.

The information provided here should not be used for self-diagnosis or self-treatment. If you are interested in retatrutide as a potential therapy, please consult with a qualified healthcare provider who can assess your individual medical situation.

Contact

For corrections, suggestions, or inquiries regarding the content on this site, please email us at info@retatrutide.med. We welcome feedback from healthcare professionals and researchers and are committed to correcting any factual errors promptly.

You can also use the forms on our Contribute page to suggest a paper, submit feedback, or sign up for our newsletter.